Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors Journal Article

   


Authors: Shih, K. K.; Zhou, Q. C.; Aghajanian, C.; Huh, J.; Soslow, R. A.; Morgan, J. C.; Iasonos, A.; Chi, D. S.; Barakat, R. R.; Abu-Rustum, N. R.
Article Title: Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors
Abstract: Objective: The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT. Methods: We performed a retrospective review of all patients with advanced-stage SBT treated at our institution from 1979 to 2008. Advanced stage was defined as FIGO stage II-IV. Progression-free survival (PFS) was defined as the time of diagnosis to time of recurrence/death or last follow-up. Kaplan-Meier method was used to report the PFS rate. Results: A total of 80 stage II-IV patients were identified, of which 15 (19%) were stage II, 63 (79%) were stage III, and 2 (2.5%) were stage IV. The site of metastasis was pelvis in 15 patients (19%), omentum in 29 patients (36%), isolated lymph nodes in 2 patients (2.5%), lung in 1 patient (1%), axilla in 1 patient (1%), and multiple sites in 32 patients (40%). With a median follow-up of 4.8 years, 17 patients (21%) developed recurrent disease. Only patients with metastasis to the omentum or multiple sites developed recurrent disease. Of the 65 stage III/IV patients, 17 patients (26%) received adjuvant chemotherapy following diagnosis. The 3-year progression-free survival (PFS) was 89.9% (95% CI, 77.3-95.7) for patients who did not receive adjuvant chemotherapy compared with 70.6% (95% CI, 43.1-86.6) for patients who received adjuvant chemotherapy. Conclusions: While advanced-stage ovarian SBT generally has a good prognosis, nearly 21% of patients develop recurrent disease with intermediate follow-up. It is unclear from these data if adjuvant chemotherapy influenced PFS. © 2010 Elsevier Inc. All rights reserved.
Keywords: adolescent; adult; aged; aged, 80 and over; disease-free survival; middle aged; retrospective studies; young adult; major clinical study; cancer localization; cancer recurrence; cisplatin; doxorubicin; advanced cancer; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; chemotherapy; cancer staging; follow up; lymph node metastasis; neoplasm staging; pelvis; ovarian neoplasms; carboplatin; metastasis; progression free survival; neoplasm recurrence, local; etoposide; recurrence; cyclophosphamide; retrospective study; lung metastasis; ovary tumor; mitoxantrone; neoplasm metastasis; kaplan meier method; cystadenocarcinoma, serous; axilla; advanced stage; ovarian borderline tumor; omentum; ovary serous borderline tumor
Journal Title: Gynecologic Oncology
Volume: 119
Issue: 2
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2010-11-01
Start Page: 270
End Page: 273
Language: English
DOI: 10.1016/j.ygyno.2010.07.019
PUBMED: 20719369
PROVIDER: scopus
PMCID: PMC4843122
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-77957750586&partnerID=40&md5=c24cdaedb1c7cd59568fc31c3828aeb5
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Richard R Barakat
    629 Barakat
  2. Dennis S Chi
    707 Chi
  3. Nadeem Abu-Rustum
    888 Abu-Rustum
  4. Qin Zhou
    253 Zhou
  5. Alexia Elia Iasonos
    362 Iasonos
  6. Karin Kuan-Hui Shih
    41 Shih
  7. Robert Soslow
    793 Soslow
  8. Jae Nyung Ward
    19 Ward
  9. Carol A Aghajanian
    607 Aghajanian
  10. Jessica Morgan
    3 Morgan
Related MSK Work